Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-3619-5p mimic is a synthetic double-stranded RNA molecule designed to mimic the endogenous tumor-suppressive microRNA miR-3619-5p. In esophageal squamous cell carcinoma (ESCC), miR-3619-5p levels are often depleted, leading to the overexpression of its target oncogene, PIM1 (proviral insertion site in Moloney murine leukemia virus 1). By restoring miR-3619-5p levels, the mimic directly binds to the 3' UTR of PIM1 mRNA, leading to its degradation or translational inhibition. This suppression results in reduced AKT phosphorylation, increased p21 expression, and subsequent inhibition of cell proliferation, migration, and invasion. Research conducted at the Kyoto Prefectural University of Medicine has demonstrated that systemic delivery of this mimic (e.g., via atelocollagen-complexed subcutaneous injection) can significantly inhibit tumor growth in xenograft models without significant systemic toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-3619-5p mimic.